Clarus Therapeutics Completes Patient Enrollment in Phase 3 Study of its Proprietary Oral Testosterone Replacement Therapy  
5/1/2012 10:13:25 AM

NORTHBROOK, Ill, May 1, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced that patient enrollment has been completed in the Company's pivotal Phase 3 clinical trial of its proprietary oral testosterone (T) replacement product (CLR-610). Primary endpoint of the ongoing study is the percentage of men who achieve normal serum T levels after administration of CLR-610 for 90 days. In addition, safety and tolerability will be assessed.